Compare Apollo Global Management Ord Shs (APO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Regeneron Pharmaceuticals Inc — how do they compare? Apollo Global Management Ord Shs trades at $140.17 (market cap $76.04B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Apollo Global Management Ord Shs and Regeneron Pharmaceuticals Inc are close in size by market cap, and Apollo Global Management Ord Shs pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| APO | REGN | |
|---|---|---|
Market Cap | $76.04B | $83.19B |
Sector | Financials | Health |
52-Week High | $152.70 | $812.27 |
52-Week Low | $100.30 | $555.51 |
Enterprise Value | -$175.45B | $77.90B |
Dividend Yield | 1.7% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $127.44, down 0.43% today but maintains a bullish technical outlook with strong analyst support. The company reported mixed Q2 2026 results with an EPS miss but record $60 billion quarterly inflows, driving AUM to $1.05 trillion. Valuation metrics show a P/E of 45.35 and P/S of 2.11, with solid profitability margins and consistent dividend payments.
APO presents a compelling investment case with strong institutional backing and growth in fee-related earnings, though elevated P/E and recent earnings miss warrant caution. The consensus price target of $151.50 suggests 19% upside potential, supported by the company's leadership in private credit and AI infrastructure expansion initiatives.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
